| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5705628 | Ophthalmology | 2016 | 12 Pages |
Abstract
Ranibizumab 0.5 mg given monthly or PRN effectively treated PEDs in patients with neovascular AMD, and significant vision gains resulted regardless of PED status and height at baseline. In this analysis, there was no additional vision benefit with a higher dose of ranibizumab (2.0 mg).
Keywords
CNVBCVAETDRSAMDRPEPRNPEDChoroidal neovascularizationstandard deviationretinal pigment epitheliumOctHarborbest-corrected visual acuityOptical coherence tomographyPigment epithelial detachmentearly treatment diabetic retinopathy studyage-related macular degenerationVascular endothelial growth factorVascular Endothelial Growth Factor (VEGF)
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
David MD, Nikolas J.S. MD, Rahul N. MD, Pravin U. MD, Shamika MD, Lauren MS, Lisa PharmD,